Abstract. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites

Discovery notes - Open Access

Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites

[Full Open Access Article: LINK. EDITED.]

Sebastian Maurer-Stroh*1, Jianmin Ma1, Raphael Tze Chuen Lee1, Fernanda L Sirota1 and Frank Eisenhaber1,2

Address: 1Biomolecular Function Discovery Division, Bioinformatics Institute (BII), Agency for Science Technology and Research (A*STAR), 30 Biopolis Street, #07-01, Matrix, 138671, Singapore and 2Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, 117543 Singapore

Email: Sebastian Maurer-Stroh* - sebastianms@bii.a-star.edu.sg; Jianmin Ma - majm@bii.a-star.edu.sg; Raphael Tze Chuen Lee - leetc@bii.astar.edu.sg; Fernanda L Sirota - fernanda@bii.a-star.edu.sg; Frank Eisenhaber - franke@bii.a-star.edu.sg
* Corresponding author


Abstract

In this work, we study the consequences of sequence variations of the "2009 H1N1" (swine or Mexican flu) influenza A virus strain neuraminidase for drug treatment and vaccination. We find that it is phylogenetically more closely related to European H1N1 swine flu and H5N1 avian flu rather than to the H1N1 counterparts in the Americas. Homology-based 3D structure modeling reveals that the novel mutations are preferentially located at the protein surface and do not interfere with the active site. The latter is the binding cavity for 3 currently used neuraminidase inhibitors: oseltamivir (Tamiflu®), zanamivir (Relenza®) and peramivir; thus, the drugs should remain effective for treatment. However, the antigenic regions of the neuraminidase relevant for vaccine development, serological typing and passive antibody treatment can differ from those of previous strains and already vary among patients.

Reviewers: This article was reviewed by Sandor Pongor and L. Aravind.
-
-----

Blogged with the Flock Browser